Yiying Zhou

2.2k total citations · 1 hit paper
63 papers, 1.7k citations indexed

About

Yiying Zhou is a scholar working on Rheumatology, Genetics and Genetics. According to data from OpenAlex, Yiying Zhou has authored 63 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Rheumatology, 14 papers in Genetics and 13 papers in Genetics. Recurrent topics in Yiying Zhou's work include Rheumatoid Arthritis Research and Therapies (22 papers), Inflammatory Bowel Disease (14 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Yiying Zhou is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (22 papers), Inflammatory Bowel Disease (14 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Yiying Zhou collaborates with scholars based in United States, China and Canada. Yiying Zhou's co-authors include Elizabeth C. Hsia, Désirée van der Heijde, Jonathan Kay, Mittie K. Doyle, Josef S Smolen, Eric L. Matteson, Robert Landewé, Frederick T. Murphy, J. Wollenhaupt and Norman Gaylis and has published in prestigious journals such as The Lancet, Gastroenterology and Applied Catalysis B: Environmental.

In The Last Decade

Yiying Zhou

55 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

2009 423 citations Josef S Smolen, Jonathan Kay et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yiying Zhou United States	19	1.1k	595	583	217	188	63	1.7k
Berta Martins da Silva Portugal	20	225 0.2×	371 0.6×	181 0.3×	124 0.6×	108 0.6×	57	1.3k
H Häntzschel Germany	20	560 0.5×	447 0.8×	102 0.2×	84 0.4×	73 0.4×	57	1.3k
Chaim M. Brickman United States	16	158 0.1×	162 0.3×	164 0.3×	66 0.3×	216 1.1×	30	1.1k
Sung Won Lee South Korea	18	337 0.3×	189 0.3×	68 0.1×	52 0.2×	29 0.2×	65	1.1k
Steven D. Rhodes United States	17	131 0.1×	95 0.2×	147 0.3×	64 0.3×	96 0.5×	53	1.3k
Clive Hawkins United Kingdom	17	163 0.2×	307 0.5×	60 0.1×	151 0.7×	28 0.1×	30	1.1k
J M De Matias Spain	9	278 0.3×	123 0.2×	94 0.2×	48 0.2×	29 0.2×	14	713
Renato Vanacore Italy	18	134 0.1×	175 0.3×	61 0.1×	40 0.2×	163 0.9×	37	1.2k
Torunn Fiskerstrand Norway	16	376 0.3×	94 0.2×	74 0.1×	214 1.0×	35 0.2×	32	1.1k
Huan Xu China	21	89 0.1×	284 0.5×	89 0.2×	49 0.2×	90 0.5×	68	1.4k

Countries citing papers authored by Yiying Zhou

Since Specialization

Citations

This map shows the geographic impact of Yiying Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yiying Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yiying Zhou more than expected).

Fields of papers citing papers by Yiying Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yiying Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yiying Zhou. The network helps show where Yiying Zhou may publish in the future.

Co-authorship network of co-authors of Yiying Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Yiying Zhou. A scholar is included among the top collaborators of Yiying Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yiying Zhou. Yiying Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Lizhi, et al.. (2024). Adjunctive clozapine with bright light mitigates cognitive deficits by synaptic plasticity and neurogenesis in sub-chronic MK-801 treated mice. Pharmacology Biochemistry and Behavior. 243. 173821–173821. 1 indexed citations

Zhou, Yiying, Ke Zhang, Fangmin Wang, et al.. (2023). Polypyrimidine tract binding protein knockdown reverses depression-like behaviors and cognition impairment in mice with lesioned cholinergic neurons. Frontiers in Aging Neuroscience. 15. 1174341–1174341.

Wang, Fangmin, Bo Yuan, Miaojun Lai, et al.. (2023). Cognitive Enhancer Donepezil Attenuates Heroin-Seeking Behavior Induced by Cues in Rats. Journal of Integrative Neuroscience. 22(3). 76–76. 3 indexed citations

Husni, M. Elaine, Atul Deodhar, Sergio Schwartzman, et al.. (2022). Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Arthritis Research & Therapy. 24(1). 11 indexed citations

Chen, Linghong, Hong Ma, Lei Gao, et al.. (2021). Fluoxetine and Ketamine Reverse the Depressive but Not Anxiety Behavior Induced by Lesion of Cholinergic Neurons in the Horizontal Limb of the Diagonal Band of Broca in Male Rat. Frontiers in Behavioral Neuroscience. 15. 602708–602708. 10 indexed citations

Panaccione, Remo, Silvio Danese, William J. Sandborn, et al.. (2020). Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Alimentary Pharmacology & Therapeutics. 52(11-12). 1658–1675. 46 indexed citations

Sandborn, William J., Brian G. Feagan, Silvio Danese, et al.. (2020). Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflammatory Bowel Diseases. 27(7). 994–1007. 77 indexed citations

Panaccione, Remo, William J. Sandborn, Bruce E. Sands, et al.. (2020). Efficacy of Ustekinumab for Ulcerative Colitis Through 2 Years: Results of the UNIFI Maintenance Study and Long-term Extension. Zeitschrift für Gastroenterologie.

Peyrin‐Biroulet, Laurent, W. Sandborn, Bruce E. Sands, et al.. (2020). Corticosteroid Sparing Effects of Ustekinumab Therapy for Ulcerative Colitis Through 2 Years: UNIFI Long-term Extension. Zeitschrift für Gastroenterologie.

10.

Zhou, Yiying, Xiang Wu, Yujing Bai, et al.. (2020). Edaravone at high concentrations attenuates cognitive dysfunctions induced by abdominal surgery under general anesthesia in aged mice. Metabolic Brain Disease. 35(2). 373–383. 20 indexed citations

11.

Kay, Jonathan, Roy Fleischmann, Edward Keystone, et al.. (2016). Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. The Journal of Rheumatology. 43(12). 2120–2130. 29 indexed citations

12.

Keystone, Edward, Mark C. Genovese, Stephen Hall, et al.. (2015). Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial. The Journal of Rheumatology. 43(2). 298–306. 35 indexed citations

13.

Deodhar, Atul, Jürgen Braun, Robert D. Inman, et al.. (2014). Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Annals of the Rheumatic Diseases. 74(4). 757–761. 101 indexed citations

14.

Wei, Bing, et al.. (2014). Edaravone's free radical scavenging mechanisms of neuroprotection against cerebral ischemia: review of the literature. International Journal of Neuroscience. 125(8). 555–565. 45 indexed citations

15.

Kavanaugh, Arthur, Iain B. McInnes, Philip J. Mease, et al.. (2014). Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Annals of the Rheumatic Diseases. 73(9). 1689–1694. 106 indexed citations

16.

Fleischmann, R, Edward Keystone, E. C. Hsia, et al.. (2014). THU0176 Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Annals of the Rheumatic Diseases. 73. 241–242.

17.

Braun, Jürgen, Xenofon Baraliakos, Kay‐Geert Hermann, et al.. (2013). The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Annals of the Rheumatic Diseases. 73(6). 1107–1113. 98 indexed citations

18.

Smolen, Josef S, Jonathan Kay, Mittie K. Doyle, et al.. (2009). Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. The Lancet. 374(9685). 210–221. 423 indexed citations breakdown →

19.

Zhou, Yiying, et al.. (2002). A stratification model of surface snow at Dome Fuji Station, Antarctica. Institutional Repository National Institute of Polar Research (National Institute of Polar Research (Japan)). 16. 61–73. 3 indexed citations

20.

Zhou, Yiying. (2001). Two Radius Support Theorem for the Sphere Transform. Journal of Mathematical Analysis and Applications. 254(1). 120–137. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact